CL2017001376A1 - Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia - Google Patents

Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia

Info

Publication number
CL2017001376A1
CL2017001376A1 CL2017001376A CL2017001376A CL2017001376A1 CL 2017001376 A1 CL2017001376 A1 CL 2017001376A1 CL 2017001376 A CL2017001376 A CL 2017001376A CL 2017001376 A CL2017001376 A CL 2017001376A CL 2017001376 A1 CL2017001376 A1 CL 2017001376A1
Authority
CL
Chile
Prior art keywords
isoindolin
piperidin
fluorophenyl
methyl
compositions
Prior art date
Application number
CL2017001376A
Other languages
English (en)
Inventor
Remy Luthringer
Masahiro Okuyama
Nadine Noel
Sandra Werner
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of CL2017001376A1 publication Critical patent/CL2017001376A1/es
Priority to CL2021000044A priority Critical patent/CL2021000044A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>LA DIVULGACIÓN PROPORCIONA UN NUEVO POLIMORFO DEL COMPUESTO (I), MONOCLORHIDRATO DE 2-((1-(2-(4-FLUOROFENIL)-2-OXOETIL) PIPERIDIN 4-IL)METIL)ISOINDOLIN-1 ONA DIHIDRATADO, ES DECIR, LA FORMA (A) DEL COMPUESTO (I)-HCI.2H2O. SE DIVULGAN TAMBIÉN COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LA FORMA (A) DEL COMPUESTO (I) HCI-2H2O Y MÉTODOS DE TRATAMIENTO RELACIONADOS.</p>
CL2017001376A 2014-12-02 2017-05-30 Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia CL2017001376A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CL2021000044A CL2021000044A1 (es) 2014-12-02 2021-01-07 Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia (divisional solicitud no. 1376-2017)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462086691P 2014-12-02 2014-12-02
US201562248071P 2015-10-29 2015-10-29

Publications (1)

Publication Number Publication Date
CL2017001376A1 true CL2017001376A1 (es) 2018-02-16

Family

ID=54848909

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017001376A CL2017001376A1 (es) 2014-12-02 2017-05-30 Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
CL2021000044A CL2021000044A1 (es) 2014-12-02 2021-01-07 Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia (divisional solicitud no. 1376-2017)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2021000044A CL2021000044A1 (es) 2014-12-02 2021-01-07 Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia (divisional solicitud no. 1376-2017)

Country Status (26)

Country Link
US (6) US9458130B2 (es)
EP (2) EP4063357A1 (es)
JP (3) JP2018501217A (es)
KR (1) KR102620681B1 (es)
CN (2) CN107567444A (es)
AU (4) AU2015355226B2 (es)
BR (1) BR112017011555B1 (es)
CA (1) CA2968977A1 (es)
CL (2) CL2017001376A1 (es)
CO (1) CO2017005498A2 (es)
DK (1) DK3227273T3 (es)
EA (1) EA201791226A1 (es)
ES (1) ES2910528T3 (es)
HU (1) HUE058212T2 (es)
IL (4) IL301320B1 (es)
MX (1) MX2017007065A (es)
MY (1) MY185516A (es)
PE (1) PE20171646A1 (es)
PH (1) PH12017501007A1 (es)
PL (1) PL3227273T3 (es)
PT (1) PT3227273T (es)
SG (1) SG11201704332YA (es)
TW (1) TWI694069B (es)
UA (1) UA122780C2 (es)
WO (1) WO2016089766A1 (es)
ZA (1) ZA201703481B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458130B2 (en) 2014-12-02 2016-10-04 Minerva Neurosciences, Inc. Compositions and methods for treating schizophrenia
JP2019516756A (ja) * 2016-05-25 2019-06-20 田辺三菱製薬株式会社 非統合失調症患者の陰性症状を治療するための方法および組成物
US11464744B2 (en) * 2017-06-21 2022-10-11 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
CN107721988A (zh) * 2017-10-31 2018-02-23 无锡福祈制药有限公司 具有抗炎活性的异吲哚‑1‑酮类化合物
CA3108882A1 (en) 2018-08-21 2020-02-27 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
TWI841545B (zh) * 2018-12-12 2024-05-11 日商田邊三菱製藥股份有限公司 耐胃性控制釋放經口劑型
US20220356165A1 (en) * 2019-06-28 2022-11-10 Teva Czech Industries S.R.O Solid state forms of roluperidone and salts thereof
JP2023526515A (ja) 2020-05-20 2023-06-21 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ リソソーム蓄積症をヒスタチンペプチドで処置するための方法
IL314859A (en) 2022-02-14 2024-10-01 Minerva Neurosciences Inc Use of rolperidone in the prevention of relapse in schizophrenia patients

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ATE102482T1 (de) 1988-01-21 1994-03-15 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit.
EP0497843A4 (en) 1989-10-27 1992-09-23 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
FR2797643B1 (fr) 1999-08-17 2003-06-06 Rhodia Chimie Sa Utilisation composes terpeniques polyoxypropylenes/ polyoxyethylenes comme agent de degraissage de surfaces dures
WO2001064670A1 (fr) * 2000-02-29 2001-09-07 Mitsubishi Pharma Corporation Nouveaux derives amide cycliques
EP1372611B1 (en) 2001-03-26 2006-05-17 Novartis AG Pharmaceutical composition comprising a poorly water-soluble staurosporine, a surfactant and a water-soluble polymer
AU2006256583B2 (en) 2005-06-06 2012-01-12 Merck Sharp & Dohme Limited Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia
CA2569776A1 (en) 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
CA2805904C (en) 2010-07-20 2022-06-21 Cyrenaic Pharmaceuticals, Inc. Use of cyclic amide derivatives to treat sigma receptor-mediated disorders
US8937900B2 (en) * 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
EP3335731B1 (en) * 2010-07-20 2024-09-04 Minerva Neurosciences, Inc. Use of cyclic amide derivatives to treat sleep disorders
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
EP2685966A1 (en) * 2011-03-17 2014-01-22 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
US10179776B2 (en) * 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
US9458130B2 (en) * 2014-12-02 2016-10-04 Minerva Neurosciences, Inc. Compositions and methods for treating schizophrenia
JP2019516756A (ja) 2016-05-25 2019-06-20 田辺三菱製薬株式会社 非統合失調症患者の陰性症状を治療するための方法および組成物
US11464744B2 (en) 2017-06-21 2022-10-11 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
CA3108882A1 (en) 2018-08-21 2020-02-27 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection

Also Published As

Publication number Publication date
IL252347B (en) 2021-01-31
BR112017011555B1 (pt) 2023-10-03
US10799493B2 (en) 2020-10-13
IL280052A (en) 2021-03-01
DK3227273T3 (da) 2022-05-02
IL301320A (en) 2023-05-01
HUE058212T2 (hu) 2022-07-28
US20180153871A1 (en) 2018-06-07
EA201791226A1 (ru) 2017-09-29
IL301320B1 (en) 2024-07-01
PL3227273T3 (pl) 2022-05-30
SG11201704332YA (en) 2017-06-29
AU2021229240B2 (en) 2023-08-24
US20210228561A1 (en) 2021-07-29
PT3227273T (pt) 2022-04-06
JP2018501217A (ja) 2018-01-18
JP2022105159A (ja) 2022-07-12
UA122780C2 (uk) 2021-01-06
IL252347A0 (en) 2017-07-31
NZ732033A (en) 2023-10-27
AU2020204286B2 (en) 2021-06-17
US20160152597A1 (en) 2016-06-02
BR112017011555A2 (pt) 2018-01-09
AU2015355226A1 (en) 2017-06-08
AU2020204286A1 (en) 2020-07-16
EP3227273B1 (en) 2022-02-09
US20170042877A1 (en) 2017-02-16
AU2021229240A1 (en) 2021-10-07
ES2910528T3 (es) 2022-05-12
US20200022968A1 (en) 2020-01-23
US10258614B2 (en) 2019-04-16
PH12017501007A1 (en) 2017-12-18
CL2021000044A1 (es) 2021-06-04
JP2020172531A (ja) 2020-10-22
TWI694069B (zh) 2020-05-21
CN107567444A (zh) 2018-01-09
ZA201703481B (en) 2023-12-20
EP4063357A1 (en) 2022-09-28
EP3227273A1 (en) 2017-10-11
JP7069253B2 (ja) 2022-05-17
KR102620681B1 (ko) 2024-01-04
CA2968977A1 (en) 2016-06-09
IL313572A (en) 2024-08-01
MX2017007065A (es) 2017-12-18
KR20170106310A (ko) 2017-09-20
IL280052B1 (en) 2023-05-01
PE20171646A1 (es) 2017-11-13
AU2015355226B2 (en) 2020-04-02
US9730920B2 (en) 2017-08-15
US9458130B2 (en) 2016-10-04
MY185516A (en) 2021-05-19
NZ770365A (en) 2023-10-27
CN111110677A (zh) 2020-05-08
WO2016089766A1 (en) 2016-06-09
US20230201184A1 (en) 2023-06-29
IL280052B2 (en) 2023-09-01
AU2023258386A1 (en) 2023-11-23
TW201632511A (zh) 2016-09-16
CO2017005498A2 (es) 2017-09-20

Similar Documents

Publication Publication Date Title
CL2017001376A1 (es) Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201790271A1 (ru) Ингибиторы гликозидазы
EA201792536A1 (ru) Триазоловые агонисты рецептора apj
TW201613872A (en) IRAK4 inhibiting agents
DK3119762T3 (da) Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft
CY1122264T1 (el) Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
DK2967049T3 (da) Metoder, forbindelser og sammensætninger til behandlingen af angiotensin relaterede sygdomme
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
DK3169405T3 (da) Fremgangsmåder, forbindelser og sammensætninger til behandling af muskel- og skeletsygdomme
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
DE112015002229A5 (de) Formulierungen zur Behandlung von Hyperthyreose
EA201691493A1 (ru) Замещенные n-арилпиридиноны
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
IT201700117749A1 (it) Composizione per trattare la costipazione
MA47193A (fr) Formes posologiques solides d&#39;inhibiteurs bace1 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridine
TH1601002537A (th) กระบวนการสำหรับการสังเคราะห์สารยับยั้งอินโดลเอมีน 2,3-ไดออกซีจีเนสชนิดหนึ่ง